^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor) +
    Xpovio (selinexor) (XPO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    THE ASCO POST
    Title:

    Phase III BOSTON Study Finds Selinexor Improves Outcomes in Myeloma

    Published date:
    07/10/2020
    Excerpt:
    Selinexor/bortezomib/dexamethasone significantly prolonged median progression-free survival compared with the doublet: 13.93 months vs 9.46 months (hazard ratio [HR] = 0.70; P = .0075). This was true for all subgroups, including patients with 17p deletions and those previously treated with lenalidomide.
    Secondary therapy:
    dexamethasone
    Trial ID:
    BOSTON
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

    Excerpt:
    The RP2D is selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle....Two of the 4 patients with documented high-risk cytogenetics at screening responded to therapy, including 1 CR t(4;14) and 1 VGPR del(17p), and were maintained on study for 17.8 and 23.0+ months, respectively...
    Secondary therapy:
    dexamethasone
    DOI:
    https://dx.doi.org/10.1182%2Fblood-2018-06-858852
    Trial ID:
    STOMP